Dr. Florian S. Eichler, MD
Neurology (Neurology Physician)
- Medicare participating
At a glance
- Years since graduation
- 29
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 23
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neurology Physician primary
MA license 225486
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Brigham and Women's Hospital Boston, MA
- Massachusetts General Hospital Boston, MA
Medical groups
- Massachusetts General Physicians Organization Inc (3,558 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 23
- Services billed
- 34
- Patients’ average age
- 60
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 17 | 13 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Payments from drug and device companies
In 2025, 3 companies reported 7 payments worth $16,044 in total to this clinician.
| Acadia Pharmaceuticals Inc | $8,538 |
|---|---|
| Sanofi US Services Inc. | $5,732 |
| Mirum Pharmaceuticals, Inc. | $1,775 |
| Compensation for services other than consulting (speaking, faculty) | $8,538 |
|---|---|
| Consulting Fee | $7,357 |
| Food and Beverage | $150 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Sanofi US Services Inc. Feb 5, 2025 | Consulting Fee | $4,169 |
| Acadia Pharmaceuticals Inc Sep 19, 2025 | Compensation for services other than consulting (speaking, faculty) | $3,938 |
| Acadia Pharmaceuticals Inc Aug 22, 2025 | Compensation for services other than consulting (speaking, faculty) | $3,850 |
| Mirum Pharmaceuticals, Inc. Jul 17, 2025 | Consulting Fee CTEXLI · Rare Disease | $1,625 |
| Sanofi US Services Inc. Oct 10, 2025 | Consulting Fee | $1,563 |
| Acadia Pharmaceuticals Inc Feb 14, 2025 | Compensation for services other than consulting (speaking, faculty) | $750 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 4 companies. The companies reported $542,381 in research payments for these studies, mostly to the institutions running them.
- An Open-Label Exploratory Study of Fosigotifator in Participants With Vanishing White Matter Disease
AbbVie Inc. · Recruiting · NCT05757141 - Long-term Follow-up of Participants With Cerebral Adrenoleukodystrophy Who Were Treated With Lenti-D Drug Product
Genetix Biotherapeutics Inc · Active, not recruiting · NCT02698579 - A Phase 1-3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ION373 in Patients With Alexander Disease
Ionis Pharmaceuticals, Inc. - A Multinational, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Pharmacodynamics, Pharmacokinetics, and Safety of Venglustat in Late-onset GM2
Sanofi US Services Inc. · Terminated · NCT04221451
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.